Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC

According to CNBC, French biotech Abivax raised nine hundred twenty million dollars, securing enough funding to launch its ulcerative colitis treatment independently rather than through acquisition. The company now has capital to sustain operations through twenty twenty-nine.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton